| abstract |
This disclosure is based on the discovery that an mdm2 / 4 inhibitor, namely (S) -1- (4-chloro-phenyl) -7-isopropoxy-6-methoxy- 2- (4- { Cyclohexylmethyl] -amino} -phenyl) -1,4-dihydro-2H-isoquinolin-3-one or (S) -5- Yl) -6- (4-chloro-phenyl) -2- (2,4-dimethoxy-pyrimidin-5- Yl) -1H-pyrrolo [3,4-d] imidazol-4-one and the cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitor 7-cyclo Pyrrolo [2,3-d] pyrimidine-6-carboxylic acid dimethylamide in the presence of a base such as triethylamine, . The present disclosure also relates to pharmaceutical combination products. This disclosure also relates to corresponding pharmaceutical agents, uses and methods of treatment comprising the mdm2 / 4 inhibitor or the cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitor. |